Generic Name and Formulations:
Conivaptan HCl 20mg/100mL in 5% dextrose; soln for IV infusion.
Cumberland Pharmaceuticals, Inc.
Indications for VAPRISOL:
Euvolemic and hypervolemic hyponatremia in hospitalized patients.
Limitations Of use:
Not effective for treating signs/symptoms of heart failure.
Administer via large veins; rotate infusion site every 24hrs. Loading dose: 20mg IV over 30mins, followed by 20mg continuous IV infusion over 24hrs. After initial day of treatment, give 20mg/day continuous IV infusion for an additional 1–3 days; may titrate up to max 40mg/day if serum sodium is not rising at desired rate. Max duration after loading dose: 4 days. Moderate and severe hepatic impairment: Loading dose: 10mg IV over 30mins, followed by 10mg/day as continuous IV infusion for 2–4 days; may titrate up to max 20mg/day if serum sodium is not rising at desired rate.
Hypovolemic hyponatremia. Concomitant potent CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir). Anuric patients.
Monitor serum sodium concentration, volume status, neurologic status. Discontinue if serum sodium rises too rapidly (>12mEq/L per 24hrs); may resume at reduced dose if hyponatremia persists or recurs and no evidence of neurologic sequelae. Discontinue if hypovolemia or hypotension develops; frequently monitor volume status and vital signs; may resume at reduced dose if euvolemic and not hypotensive. Severe renal impairment: not recommended. Pregnancy. Nursing mothers: not recommended.
See Contraindications. Potentiated by CYP3A4 inhibitors. Potentiates CYP3A4 substrates (eg, midazolam, simvastatin, amlodipine); avoid; allow at least 1 week after end of conivaptan administration before resuming these drugs. May potentiate digoxin; monitor.
Dual arginine vasopressin (V1A and V2) receptors antagonist.
Infusion site reactions (eg, phlebitis, erythema, pain), GI upset, headache, hypokalemia, hyponatremia, orthostatic hypotension, hyper- or hypotension, peripheral edema, thirst, pyrexia.
Single-use premixed soln—1
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- A Witness to Letting Go: Nursing Care at the End of Life
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Intervention Improves Breast Cancer Survivors' Memory Contentment
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Patients With Head and Neck Cancer Have Greater Chance of Being Prescribed Opioids
- Medical Terms in Patient Education: Using the Confusing to Explain the Complicated
- Bedside Assessment Tool Improves Worst Pain in Patients With Cancer
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- USPSTF Rates Ovarian Cancer Screening a D for Asymptomatic, Low-Risk Women
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|